Koh, Siang-Boon http://orcid.org/0000-0002-5494-3800
Dontchos, Brian N.
Bossuyt, Veerle
Edmonds, Christine
Cristea, Simona
Melkonjan, Nsan
Mortensen, Lindsey
Ma, Annie
Beyerlin, Kassidy
Denault, Elyssa
Niehoff, Elizabeth http://orcid.org/0000-0002-4777-3700
Hirz, Taghreed
Sykes, David B.
Michor, Franziska
Specht, Michelle
Lehman, Constance
Ellisen, Leif W. http://orcid.org/0000-0003-0444-7910
Spring, Laura M. http://orcid.org/0000-0001-8904-3514
Funding for this research was provided by:
Massachusetts General Hospital ESCCO Breast Cancer Research Fund
Article History
Received: 10 April 2021
Accepted: 20 August 2021
First Online: 21 September 2021
Competing interests
: BD is an ad-hoc consultant for GE Healthcare. DBS is a co-founder and holds equity in Clear Creek Bio, is a consultant and holds equity in SAFI Biosolutions, and is a consultant for Keros Therapeutics. LMS reports consulting fees from Novartis and Avrobio. All other authors declare no competing interests related specifically to this work.